Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MGAM | O43451 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | FASN | P49327 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11030634 | 0.88 | MAOA (0.41) | MAOAPTPN1POLBADORA3 | |
| SCHEMBL11028326 | 0.87 | MAOA (0.46) | MAOAPOLBMGAMGAASI | |
| SCHEMBL11029164 | 0.86 | MAOA (0.48) | MAOAPTPN1POLBMGAMGAA | |
| SCHEMBL11031797 | 0.79 | MAOA (0.70) | MAOAMGAMACHEMAOBTOP2A | |
| SCHEMBL11030838 | 0.77 | MGAM (0.70) | MAOAPTPN1MGAMGAASI | |
| SCHEMBL20567443 | 0.77 | MAPT (0.68) | MAOAMAOB | |
| SCHEMBL11029670 | 0.76 | MAOA (0.54) | MAOAPOLBMGAMGAASI | |
| SCHEMBL11029063 | 0.75 | MAOA (0.40) | MAOAADORA3 | |
| SCHEMBL11030589 | 0.74 | MAOA (0.62) | MAOAPOLBMGAMGAASI | |
| SCHEMBL11029434 | 0.74 | MAOA (0.42) | MAOAACHEMAOBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-07-26 | — | — | US | claimed |
| US-8846749-B2 | Anticancer-aiding compound, method for preparing the same, anticancer-aiding composition containing the same and method for reducing anticancer drug resistance using the same | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2014-09-30 | — | — | US | disclosed |
| US-8846749-B2 | Anticancer-aiding compound, method for preparing the same, anticancer-aiding composition containing the same and method for reducing anticancer drug resistance using the same | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2014-09-30 | — | — | US | disclosed |
| US-8846749-B2 | Anticancer-aiding compound, method for preparing the same, anticancer-aiding composition containing the same and method for reducing anticancer drug resistance using the same | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2014-09-30 | — | — | US | disclosed |
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-07-26 | — | — | US | disclosed |
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-07-26 | — | — | US | disclosed |
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190724-A1 | NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME | ABCC1, ANXA1, ANXA5 | MAOA 4052/4885PTPN1 2474/4885POLB 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.